En undersøgelse af LY3867070 hos raske deltagere
En enkelt- og multiple-asaskende dosisundersøgelse for at evaluere sikkerheden og farmakokinetikken i LY3867070 hos raske deltagere
The purpose of this study is to evaluate how well LY3867070 is tolerated and what side effects may occur in healthy participants. The study drug will be administered orally. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
California
-
Anaheim, California, Forenede Stater, 92801
- Anaheim Clinical Trials, LLC
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75247
- Fortrea Clinical Research Unit
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Are overtly healthy as determined by medical evaluation
- Part C of the study includes only Japanese and Chinese participants
- Have a body weight greater than or equal to 45 kilogram (kg) and also body mass index 18 to 32 kilogram per square meter (kg/m²) inclusive
Exclusion Criteria:
- Have a history or presence of multiple or severe allergies, anaphylactic reaction to prescription or nonprescription drugs, or history of significant atopy
- Have a significant history or current thyroid disease
- Have a significant history of or current psychiatric disorders, rheumatologic, cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine (such as Cushing syndrome and hyperaldosteronism), hematological, or neurological disorders
- Are smokers (including electronic cigarettes) within 6 months prior to screening and unwilling to refrain from smoking for the duration of the study.
- Unwilling to undergo skin biopsies (for Part B only)
- Are unwilling to have body hair cut or shaved in cases where hair, in the investigator's opinion, could interfere with noninvasive skin patch
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: LY3867070 (Part A)
Single-Ascending Dose of LY3867070 administered orally |
Administered orally |
|
Eksperimentel: LY3867070 (Part B)
Multiple-Ascending Doses of LY3867070 administered orally |
Administered orally |
|
Eksperimentel: LY3867070 (Part C)
Multiple Doses of LY3867070 administered orally |
Administered orally |
|
Placebo komparator: Placebo (Parts A-C)
Placebo administered orally |
Administered orally |
|
Eksperimentel: LY3867070 (Part D)
Drug-Drug Interaction (DDI) administered orally |
Administered orally |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) Considered by the Investigator to be Related to Study Drug Administration
Tidsramme: Baseline up to Approximately Week 7
|
A summary of TEAEs regardless of causality, will be reported in the Reported Adverse Events module |
Baseline up to Approximately Week 7
|
|
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Tidsramme: Baseline up to Approximately Week 7
|
A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module |
Baseline up to Approximately Week 7
|
|
Number of Participants with One or More Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration
Tidsramme: Baseline up to Approximately Week 7
|
A summary of AEs regardless of causality, will be reported in the Reported Adverse Events module |
Baseline up to Approximately Week 7
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3867070
Tidsramme: Baseline up to Approximately Week 7
|
PK: AUC of LY3867070 |
Baseline up to Approximately Week 7
|
|
PK: Maximum Concentration (Cmax) of LY3867070
Tidsramme: Baseline up to Approximately Week 7
|
PK: Cmax of LY3867070 |
Baseline up to Approximately Week 7
|
|
Part B Pharmacodynamic (PD): Change from Baseline in Gene Expression
Tidsramme: Baseline up to Approximately Week 6
|
PD: Change from Baseline in Gene Expression |
Baseline up to Approximately Week 6
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 18873
- J5H-MC-KVAA (Anden identifikator: Eli Lilly and Company)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .